Skip to main content

Profound Medical Corp.

corporate_fare Company Profile

Profound Medical Corp.

PROF·NASDAQ·Industrial Applications And Services·CIK 0001628808

We are a commercial-stage medical device company focused on developing and marketing AI-powered, MRI-guided, incision-free therapies for ablating diseased tissue using our platform technologies. Our main product, the TULSA-PRO system, integrates real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound, and closed-loop temperature feedback control to ablate either the entire gland or a physician-defined region of malignant or benign prostate tissue. The TULSA-PRO system has demonstrated effectiveness in clinical and commercial settings for physicians treating prostate diseases, including cancer and benign prostatic hyperplasia ("BPH"). In August 2019, the TULSA-PRO system received FDA clearance as a Class II device in the United States for thermal ablation of prescribed prostate tissue, based on the Company's TACT whole gland ablation pivotal study. It also holds CE Mark approval in the EU for ablation of targeted prostate tissue (benign or malignant) and was approved by Health Canada in November 2019. Our Sonalleve system is CE Marked in the EU for ablation of uterine fibroids and adenomyotic tissue, palliative pain relief for bone metastases, treatment of osteoid osteoma, and management of benign desmoid tumors. The Sonalleve system is also approved in China and South Korea for non-invasive treatment of uterine fibroids. In November 2020, the Sonalleve system received HDE approval from the FDA for treating osteoid osteoma in the extremities. Our systems are designed for use with MRI scanners and are currently compatible with select MRI scanners from Philips, Siemens, and GE Healthcare. We have generated revenues from commercializing our systems in the United States, EU, and Asia.

Profound Medical Corp. (NASDAQ:PROF) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 29 items for PROF at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Profound Medical to Host Investor Call on March 13 to Discuss First Clinical Outcomes from Pivotal CAPTAIN Trial
  • Profound Medical Reports Strong Revenue Growth, Key Clinical Milestones, and Successful Capital Raise in Annual Report
  • Profound Medical Reports Record Q4 Revenue, Strong Pipeline Growth, and Appoints Medical Device Veteran to Board
  • Profound Medical Honored with Mount Logan Award, Citing 4,000 TULSA Procedures & New Medicare Reimbursement
  • Profound Medical's Sonalleve Reaches 500 Procedures at PRO FAMILIA Hospital, Highlighting International Growth

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$16.1M
Net Income
-$42.57M
Diluted EPS
$1.41
Op. Cash Flow
-$38.21M
Gross Profit
$11.39M
Operating Income
-$41.25M
Cash & Equivalents
$59.72M
Total Debt
$4.5M
Debt / Equity
0.07×
Net Margin
-264.4%
Shares Outstanding
36.29M sh
Source: 10-K · filed 2026-03-05 · accession 0001104659-26-024153
$6.38
52-week range · as of 2026-11-12 $4.8 – $8.95
Market cap
$233.68M
Volume
144.2K (0.8× avg)
3-mo avg 190.8K
Live data · 2026-11-22 08:20 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PROF - Filings & News (Page 2)

PROF
Mar 09, 2026, 9:55 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.00
Real-time Price: $6.38 info
Change: +$1.38 (+28%) info
Market Cap: $233.679M info
PROF
Mar 05, 2026, 4:32 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $6.90
Real-time Price: $6.38 info
Change: -$0.520 (-8%) info
Market Cap: $233.679M info
PROF
Mar 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.38
Real-time Price: $6.38 info
Change: $0 (0%) info
Market Cap: $233.679M info
PROF
Feb 12, 2026, 8:33 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.36
Real-time Price: $6.38 info
Change: +$0.020 (+0.31%) info
Market Cap: $233.679M info
PROF
Feb 05, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.82
Real-time Price: $6.38 info
Change: -$0.440 (-6%) info
Market Cap: $233.679M info
PROF
Jan 15, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.55
Real-time Price: $6.38 info
Change: -$2.17 (-25%) info
Market Cap: $233.679M info
PROF
Jan 12, 2026, 11:37 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.59
Real-time Price: $6.38 info
Change: -$2.21 (-26%) info
Market Cap: $233.679M info
PROF
Jan 06, 2026, 1:40 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.53
Real-time Price: $6.38 info
Change: -$1.15 (-15%) info
Market Cap: $233.679M info
PROF
Jan 02, 2026, 8:40 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.87
Real-time Price: $6.38 info
Change: -$1.49 (-19%) info
Market Cap: $233.679M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets